Market data not licensed for redistribution.

SAM Chun Dang Pharm

000250 · KOSDAQ · Pharmaceuticals Manufacturing

– Previous close pending (official data.go.kr feed not active yet) Live price ↗

Source: Financial Services Commission stock price data (data.go.kr), updated once a day.

Daily price, 1 year

Key statistics

Market cap (KRW bn)–

PER–

PBR–

ROE %6.4

Debt ratio % (liabilities / equity)44

Revenue TTM (KRW bn)259.9

Op. profit TTM (KRW bn)17.7

Dividend yield %–

Basis: market cap at …; equity = total equity (consolidated if available) at 2026.06.30; net income = trailing 12 months to 2026.06.30 (consolidated). PER is not shown when TTM net income is negative.

Upcoming risk events

Next 90 days for this company, plus macro events tagged with this ticker or its sector. Not a recommendation.

No scheduled risk events found (last checked 2026-10-30 19:40 KST).

See it in the full calendar →

Annual results (KRW bn)

	2021	2022	2023	2024	2025
Revenue	167.3	177.3	192.7	210.9	231.8
Operating profit	-15.3	12.2	9.6	2.6	8.5
Net income	-10.4	8.8	-4.2	-5.1	12.0

Quarterly results (KRW bn, 3 months)

	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	50.6	56.9	58.0	66.3	64.9	70.7
Operating profit	0.7	-1.1	3.4	5.4	5.4	3.4
Net income	1.3	-1.6	4.5	7.9	6.9	6.2

Largest shareholder

As of the 2025 annual report: (주)소화 and related parties hold 37.60% of common shares.

Recent disclosures

Date	Filing
2026-10-20	Insider / major-holder ownership report 주식등의대량보유상황보고서(일반)	DART original
2026-10-08	Periodic report (annual/half/quarterly) [기재정정]반기보고서 (2026.06)	DART original
2026-10-08	Periodic report (annual/half/quarterly) [기재정정]분기보고서 (2026.03)	DART original
2026-10-01	Single sales/supply contract [기재정정]투자판단관련주요경영사항 (황반변성치료제(아일리아/주성분 : Aflibercept) 바이오시밀러 SCD411(Vial&PFS)의 캐나다 독점판매권 공급계약 체결 및 중동 6개 국가 추가 계약 체결)	DART original
2026-08-14	Insider / major-holder ownership report 주식등의대량보유상황보고서(일반)	DART original
2026-08-14	Periodic report (annual/half/quarterly) 반기보고서 (2026.06)	DART original
2026-08-05	Clinical trial / regulatory approval [기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (제1형 당뇨병 환자를 대상으로 정상혈당 클램프 조건 및 식이 섭취 후, 경구용 인슐린 SCD0503과 피하 투여 인슐린 간의 상대적 생체이용률, 상대적 생물학적 효력 및 음식 영향 평가를 위한 임상시험)	DART original
2026-08-05	Clinical trial / regulatory approval [기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (제1형 당뇨병 환자를 대상으로 정상혈당 클램프 조건 및 식이 섭취 후, 경구용 인슐린 SCD0503과 피하 투여 인슐린 간의 상대적 생체이용률, 상대적 생물학적 효력 및 음식 영향 평가를 위한 임상시험)	DART original
2026-07-23	Insider / major-holder ownership report 주식등의대량보유상황보고서(일반)	DART original
2026-06-30	Shareholder meeting 임시주주총회결과	DART original
2026-06-30	Governance / misc. (routine) 독립이사의선임ㆍ해임또는중도퇴임에관한신고	DART original
2026-06-12	Shareholder meeting 주주총회소집공고	DART original

Past material filings and price reaction (market-adjusted)

Date	Filing type	On the news (vs. market)	Next day (vs. market)	20 days (vs. market)
2026-05-29	Clinical trial / regulatory approval	+12.2%	-7.8%	-21.4%
2026-04-20	Delisting / administrative issue designation	+1.8%	-2.5%	-18.3%
2026-03-31	Unfaithful-disclosure notice	-11.9%	-4.5%	-54.6%
2026-03-30	Other material event (investment-relevant)	-3.2%	-22.9%	-72.5%
2026-03-19	Clinical trial / regulatory approval	+3.2%	+12.5%	-38.2%
2026-02-26	Other material event (investment-relevant)	+27.9%	+8.6%	+50.7%
2026-02-10	Revenue/profit change >=30% (15% large caps)	-3.9%	-0.6%	+40.2%
2026-02-10	Cash/stock dividend decision	-3.9%	-0.6%	+40.2%
2025-10-22	Acquisition of shares in another company	-0.9%	-1.0%	+7.5%
2025-09-22	Clinical trial / regulatory approval	+3.4%	-2.6%	-18.1%

For information only, not investment advice. Data may be delayed or inaccurate. Full disclaimer → Data: OpenDART (FSS), stock prices: official previous-day close from the Financial Services Commission (data.go.kr) and FinanceData/marcap history, index data via FinanceDataReader, FX: ECB reference rates, crypto data from Upbit, Bithumb and Binance public APIs.
Market data not licensed for redistribution.
© Crypvu · Crypto market view